Scancell HoldingsSCNLF 20 Days Payable is 0.00 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, Scancell Holdings ranks better than 92.93% on this metric.
The historical rank and industry rank for Scancell Holdings's Days Payable or its related term are showing as below:
SCNLF'
s Days Payable Range Over the Past 10 Years
Min: 1197.9 Med: 1391.45 Max: 4240.95
Current: 4240.95
During the past 13 years, Scancell Holdings's highest Days Payable was 4240.95. The lowest was 1197.90. And the median was 1391.45.
SCNLF's Days Payable is ranked better than 92.93% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs SCNLF: 4240.95
Scancell Holdings's Days Payable
stayed the same
from Oct. 2024 (0.00) to Oct. 2025 (0.00).
Scancell Holdings Days Payable Related Terms
Scancell Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNLF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Scancell Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Scancell Holdings's Days Payable for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a Days Payable of 0.00 as of Oct. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Scancell Holdings and its competitors. Over the past decade, Scancell Holdings' Days Payable has ranged from 1,197.90 to 4,240.95. According to the industry distribution chart, Scancell Holdings ranks #50 out of 707 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Scancell Holdings' Days Payable too high?
Scancell Holdings' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,197.90 to a high of 4,240.95. Based on the distribution chart, Scancell Holdings ranks #50 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #50 out of 707 companies for Days Payable. This places Scancell Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Historically, Scancell Holdings' own Days Payable has ranged from 1,197.90 to 4,240.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Scancell Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Days Payable of 0.00. The current Days Payable is 0.00. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Days Payable is 0.00 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score
Get the complete analysis for SCNLF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
